117 related articles for article (PubMed ID: 37649401)
1. LGALS3BP is a potential target of antibody-drug conjugates in oral squamous cell carcinoma.
Cela I; Caponio VCA; Capone E; Pinti M; Mascitti M; Togni L; Lo Muzio L; Rubini C; De Laurenzi V; Lattanzio R; Perrotti V; Sala G
Oral Dis; 2024 May; 30(4):2039-2050. PubMed ID: 37649401
[TBL] [Abstract][Full Text] [Related]
2. Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma.
Dufrusine B; Capone E; Ponziani S; Lattanzio R; Lanuti P; Giansanti F; De Laurenzi V; Iacobelli S; Ippoliti R; Mangiola A; Trevisi G; Sala G
Mol Oncol; 2023 Aug; 17(8):1460-1473. PubMed ID: 37195369
[TBL] [Abstract][Full Text] [Related]
3. Increased LGALS3BP promotes proliferation and migration of oral squamous cell carcinoma via PI3K/AKT pathway.
Zhang X; Ding H; Lu Z; Ding L; Song Y; Jing Y; Hu Q; Dong Y; Ni Y
Cell Signal; 2019 Nov; 63():109359. PubMed ID: 31302247
[TBL] [Abstract][Full Text] [Related]
4. Impact of Spatially Heterogeneous Trop-2 Expression on Prognosis in Oral Squamous Cell Carcinoma.
Erber R; Spoerl S; Mamilos A; Krupar R; Hartmann A; Ruebner M; Taxis J; Wittenberg M; Reichert TE; Spanier G; Spoerl S
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008509
[TBL] [Abstract][Full Text] [Related]
5. Potential of tumor-suppressive miR-596 targeting LGALS3BP as a therapeutic agent in oral cancer.
Endo H; Muramatsu T; Furuta M; Uzawa N; Pimkhaokham A; Amagasa T; Inazawa J; Kozaki K
Carcinogenesis; 2013 Mar; 34(3):560-9. PubMed ID: 23233740
[TBL] [Abstract][Full Text] [Related]
6. Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma.
Capone E; Perrotti V; Cela I; Lattanzio R; Togni L; Rubini C; Caponio VCA; Lo Muzio L; Colasante M; Giansanti F; Ippoliti R; Iacobelli S; Wick MJ; Spardy Burr N; Sala G
Oral Oncol; 2024 Jan; 148():106635. PubMed ID: 37988837
[TBL] [Abstract][Full Text] [Related]
7. Validation of Salivary Markers, IL-1β, IL-8 and Lgals3bp for Detection of Oral Squamous Cell Carcinoma in an Indian Population.
Singh P; Verma JK; Singh JK
Sci Rep; 2020 Apr; 10(1):7365. PubMed ID: 32355279
[TBL] [Abstract][Full Text] [Related]
8. Knocking-down of CREPT prohibits the progression of oral squamous cell carcinoma and suppresses cyclin D1 and c-Myc expression.
Ma J; Ren Y; Zhang L; Kong X; Wang T; Shi Y; Bu R
PLoS One; 2017; 12(4):e0174309. PubMed ID: 28369091
[TBL] [Abstract][Full Text] [Related]
9. The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma.
Feng X; Luo Q; Zhang H; Wang H; Chen W; Meng G; Chen F
J Exp Clin Cancer Res; 2017 Jun; 36(1):81. PubMed ID: 28637493
[TBL] [Abstract][Full Text] [Related]
10. Salivary extracellular vesicle-associated miRNAs as potential biomarkers in oral squamous cell carcinoma.
Gai C; Camussi F; Broccoletti R; Gambino A; Cabras M; Molinaro L; Carossa S; Camussi G; Arduino PG
BMC Cancer; 2018 Apr; 18(1):439. PubMed ID: 29669525
[TBL] [Abstract][Full Text] [Related]
11. Identification and Validation of PLOD2 as an Adverse Prognostic Biomarker for Oral Squamous Cell Carcinoma.
Sun Y; Wang S; Zhang X; Wu Z; Li Z; Ding Z; Huang X; Chen S; Jing Y; Zhang X; Ding L; Song Y; Sun G; Ni Y
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944486
[TBL] [Abstract][Full Text] [Related]
12. Proteomic Profiling of Paired Interstitial Fluids Reveals Dysregulated Pathways and Salivary NID1 as a Biomarker of Oral Cavity Squamous Cell Carcinoma.
Hsu CW; Chang KP; Huang Y; Liu HP; Hsueh PC; Gu PW; Yen WC; Wu CC
Mol Cell Proteomics; 2019 Oct; 18(10):1939-1949. PubMed ID: 31315917
[TBL] [Abstract][Full Text] [Related]
13. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
14. Parathyroid hormone-related protein serves as a prognostic indicator in oral squamous cell carcinoma.
Lv Z; Wu X; Cao W; Shen Z; Wang L; Xie F; Zhang J; Ji T; Yan M; Chen W
J Exp Clin Cancer Res; 2014 Dec; 33(1):100. PubMed ID: 25539663
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of cancer-associated fibroblast-derived extracellular vesicles on cisplatin resistance in oral squamous cell carcinoma
Kang SH; Oh SY; Lee KY; Lee HJ; Kim MS; Kwon TG; Kim JW; Lee ST; Choi SY; Hong SH
Theranostics; 2024; 14(2):460-479. PubMed ID: 38169528
[No Abstract] [Full Text] [Related]
16. NLRP3 promotes tumor growth and metastasis in human oral squamous cell carcinoma.
Wang H; Luo Q; Feng X; Zhang R; Li J; Chen F
BMC Cancer; 2018 May; 18(1):500. PubMed ID: 29716544
[TBL] [Abstract][Full Text] [Related]
17. Expression of FAP in Oral Leukoplakia and Oral Squamous Cell Carcinoma.
Li R; Zhang R; Shi X; Jiao X; Li Y; Zhao Y; Liu T; Zhang C
Int Dent J; 2024 Jun; 74(3):581-588. PubMed ID: 38278714
[TBL] [Abstract][Full Text] [Related]
18. Differences in the response of normal oral mucosa, oral leukoplakia, oral squamous cell carcinoma-derived mesenchymal stem cells, and epithelial cells to photodynamic therapy.
Guo Q; Ji X; Zhang L; Liu X; Wang Y; Liu Z; Jin J; Han Y; Liu H
J Photochem Photobiol B; 2024 Jun; 255():112907. PubMed ID: 38677259
[TBL] [Abstract][Full Text] [Related]
19. Hsa_circ_0008309 May Be a Potential Biomarker for Oral Squamous Cell Carcinoma.
Li B; Wang F; Li X; Sun S; Shen Y; Yang H
Dis Markers; 2018; 2018():7496890. PubMed ID: 30344795
[TBL] [Abstract][Full Text] [Related]
20. Exploration of Alternative Mechanism for MiR-596-mediated Down-regulation of LGALS3BP in Oral Squamous Cell Carcinoma.
Li H
Kokubyo Gakkai Zasshi; 2015 Jul; 82(2):55-61. PubMed ID: 26502662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
